Rivaroxaban
| Clinical data | |
|---|---|
| Trade names | Xarelto, others |
| Other names | BAY 59-7939 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a611049 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80–100%; Cmax = 2–4 hours (10 mg oral)[5] |
| Metabolism | CYP3A4, CYP2J2 and CYP-independent mechanisms[5] |
| Elimination half-life | 5–9 hours in healthy subjects aged 20 to 45[5][8] |
| Excretion | 2/3 metabolized in liver and 1/3 eliminated unchanged[5] |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| PDB ligand | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.210.589 |
| Chemical and physical data | |
| Formula | C19H18ClN3O5S |
| Molar mass | 435.88 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and reduce the risk of blood clots.[9] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery.[9] It is taken by mouth.[9]
Common side effects include bleeding.[9] Other serious side effects may include spinal hematoma and anaphylaxis.[9] It is unclear if use in pregnancy and breastfeeding is safe.[1] Compared to warfarin it has fewer interactions with other medications.[10] It works by blocking the activity of the clotting protein factor Xa.[9]
Rivaroxaban was patented in 2007 and approved for medical use in the United States in 2011.[11] It is available as a generic medication.[12] It is on the World Health Organization's List of Essential Medicines.[13] In 2022, it was the 90th most commonly prescribed medication in the United States, with more than 7 million prescriptions.[14][15]
- ^ a b "Rivaroxaban Use During Pregnancy". Drugs.com. Retrieved March 3, 2019.
- ^ Xarelto (Bayer Australia Ltd)
- ^ "Summary Basis of Decision for Xarelto". Drug and Health Products Portal. February 13, 2009. Retrieved March 11, 2025.
- ^ "Regulatory Decision Summary for Xarelto". Drug and Health Products Portal. January 12, 2021. Retrieved March 11, 2025.
- ^ a b c d e "Xarelto 2.5 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). August 9, 2022. Retrieved November 9, 2022.
- ^ Cite error: The named reference
Xarelto FDA labelwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Xarelto EPARwas invoked but never defined (see the help page). - ^ Abdulsattar Y, Bhambri R, Nogid A (May 2009). "Rivaroxaban (xarelto) for the prevention of thromboembolic disease: an inside look at the oral direct factor xa inhibitor". P & T : a Peer-reviewed Journal for Formulary Management. 34 (5): 238–244. PMC 2697099. PMID 19561868.
- ^ a b c d e f "Rivaroxaban Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved March 3, 2019.
- ^ Kiser K (2017). Oral Anticoagulation Therapy: Cases and Clinical Correlation. Springer. p. 11. ISBN 978-3-319-54643-8.
- ^ "Generic Xarelto Availability". Drugs.com. Retrieved May 9, 2017.
- ^ "FDA Roundup: March 4, 2025". U.S. Food and Drug Administration (Press release). March 4, 2025. Retrieved March 7, 2025.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
- ^ "The Top 300 of 2022". ClinCalc. Archived from the original on August 30, 2024. Retrieved August 30, 2024.
- ^ "Rivaroxaban Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved August 30, 2024.